Iron-Magnesium Hydroxycarbonate
Trade name: Fermagate
Small moleculeexperimental
Fermagate is a new inorganic phosphate binder developed for the control of blood plasma phosphate, a key therapeutic aim in the prevention of hyperphosphataemia in haemodialysis patients. It is currently under evaluation in clinical trials. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT00317694)
Timeline
Indications
Studied for
Mechanism of action
- PhosphateSEQUESTERING AGENT
sequestering agent - phosphate
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFermagate ↗
Also known as
- fermagate
- fermagate
- fermagate
- iron-magnesium hydroxycarbonate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00844662 | Phase 3 | Jul 1, 2009 | Ineos Healthcare Limited |
| NCT00436683 | Phase 2 | Feb 1, 2007 | Ineos Healthcare Limited, University of Nottingham |
| NCT00358722 | Phase 2 | Jul 1, 2006 | Ineos Healthcare Limited, University of Nottingham |
| NCT00317694 | Phase 2 | Mar 1, 2006 | Ineos Healthcare Limited, University of Nottingham |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ineos Healthcare Limited | For profit | 4 | 4 | 2 | 2006 |
| University of Nottingham | Academic/Hospital | 3 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1